Biofrontera Inc. (BFRI)

Overview

Biofrontera Inc. is a biopharmaceutical entity that specializes in the development and commercialization of novel treatments targeting specific dermatological conditions. Since its inception in 2015, the company has focused its efforts on addressing skin disorders that necessitate medical interventions, providing therapeutic solutions primarily within the United States. The cornerstone of Biofrontera's mission hinges on the innovation of pharmaceutics that can efficiently manage and treat pre-cancerous skin lesions known as actinic keratoses, as well as impetigo, a prevalent bacterial skin infection. With its headquarters stationed in Woburn, Massachusetts, Biofrontera leverages its expertise in dermatology to improve patient outcomes and contribute meaningful advancements in skin health.

Products and Services

The therapeutic offerings from Biofrontera Inc. are characterized by their specialized application in dermatological care, especially focusing on lesion-directed and field-directed treatments.

• Ameluz: This prescription medicament is designed for the efficacious management of actinic keratosis of mild-to-moderate severity, localized on the face and scalp. When used in conjunction with the RhodoLED lamp series, Ameluz is administered through photodynamic therapy (PDT), a modern approach that enhances the drug's efficacy by leveraging the power of light. This treatment methodology targets the affected skin areas while minimizing damage to the surrounding healthy tissue.
• Xepi: As a topical non-fluorinated quinolone, Xepi plays a crucial role in curbing the growth of bacteria, thereby offering a potent remedy for impetigo. This antibiotic cream stands out by its ability to fight off bacterial infections without promoting the development of antibiotic-resistant strains, ensuring an effective defense against impetigo. Given its targeted mechanism of action, Xepi represents a significant advancement in topical antibacterial treatments available to patients.